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The Redox Status of Coenzyme Q10 in Total
LDL as an Indicator of In Vivo
Oxidative Modification
Studies on Subjects With Familial Combined Hyperlipidemia
Yolanda B. de Rijke,:|: Sebastian J.H. Bredie,* Pierre N.M. Demacker, Janine M.
Heidi L.M. Hak-Lemmers, Anton F.H. Stalenhoef
Abstract Familial combined hyperlipidemia (FCH) is char­
acterized by a familial occurrence of a multiple-type hyperlipid­
emia, associated with coronary risk. The latter may be related to 
increased levels of small, dense LDL particles that have been 
found to be more prone to oxidative modification. We isolated 
total LDL as fresh as possible from 12 normolipidemic relatives 
with a buoyant LDL subfraction profile (group 1), 7 normolip­
idemic subjects with a dense LDL subtraction profile (group 2), 
and 16 hyperlipidemie FCH subjects with a dense LDL subfrac­
tion profile (group 3). In these nonobese and normotensive men, 
we studied the resistance of total LDL against C u2+-oxidation in 
vitro. In addition, we analyzed the a-tocopherol and the coen­
zyme Q10 contents of LDL and determined their relation to LDL 
oxidizability. LDL isolated from group 3 subjects was more sus­
ceptible to oxidative modification than LDL from group 1 sub­
jects (lag time: 60 .4±8 .1 versus 70.4± 11.4 minutes; P<.{)5). For 
the combined groups, the ratio of ubiquinol-10 to polyunsaturated
fatty acids in LDL, together with the basal amount of dienes in 
LDL, were good predictors of the rale of LDL oxidation ( / i ’=.73, 
P=.00()I). In groups 2 and 3, the redox status of coenzyme Q10 
(ubiquinol- 10/ubiquinone-10) and the ratio of ubiquinol-10 to 
a-tocopherol in LDL were reduced compared with group 1 
(ƒ*<.()5). The K-value, a measure of the LDL density, correlated 
with the the redox status (r=.37, P<A)5). We conclude that in 
subjects with FCH total LDL is more prone to oxidation, due to 
the predominance of dense LDL particles. In addition, the de­
creased redox status of coenzyme Q 10 in LDL from subjects with 
a dense LDL subfraction profile suggests that the LDL in the 
circulation has already undergone some oxidation. (Arterioscler
Thro mb Vase Biol. 1997:17:127-133.)
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amilial combined (FCH),
identified by Goldstein et a l ,1 is a genetically 
and metabolically heterogeneous common lipid 
disorder, associated with an increased risk for cardio­
vascular disease. '-2 The trait is characterized by a mul­
tiple-type hyperlipidemia in iirst-degree relatives. Af­
fected persons exhibit elevated plasma concentrations 
of cholesterol or triglycerides, or both. In addition, el­
evated concentrations of apolipoprotein B and reduced 
concentrations of HDL-C are observed. Furthermore, 
FCH has been shown to be associated with a predom­
inance of dense LDL subfniction profiles.M Small, 
dense LDL was generally found to be prevalent in pa­
tients with coronary heart disease.5 1(1
Studies on LDL oxidation revealed that small, dense 
LDL particles are more prone to oxidative modification 
than buoyant LDL.1112 Oxidation of LDL is believed to 
play an important role in early atherosclerosis.1’ After 
being oxidatively modified in the intima, LDL is probably 
taken up by scavenger receptors of macrophages.14 As a
result of uncontrolled uptake of oxidized LDL, macro­
phages are converted into cholesterol-rich foam cells, a 
hallmark of early atherosclerotic lesions.15 Evidence in 
humans to support the oxidation hypothesis has been pro­
vided by studies that showed an association between 
plasma autoantibodies against oxidatively modified LDL 
and the progression of cardiovascular disease.1^ 17 Epi­
topes of oxidized LDL also were detected in human fatty 
streaks.IK-19
According to the oxidation hypothesis, LDL is pro­
tected against oxidative stress by antioxidants, thereby 
delaying the formation of modified LDL. The lipophilic 
antioxidants cv-TOH, QHU-10, /3-carotene, and lyeopene 
are present in LDL.2H Epidemiological studies suggested 
that high (>100 mg/d) cv-TOI 1 intake contributes to re­
duced risk of atherosclerosis.21-’2 Although a-TOH is be-
lieved to be the major antioxidant in responsible for
the protection against oxidation in vivo,20 extensive work 
by Stocker and co-workers (reviewed in Reference 23) 
suggests that the determination of the LDL QHU-IO con­
tent is more relevant to assess the initial state of LDL
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peroxidation in vivo. QHU-10 (or reduced coenzyme Q) 
is an endogenous product of the mevanolate pathway, 
having coenzymatic activity in the enzyme system of mi­
tochondria, where it functions as an essential electron car­
rier in the respiratory system.2,1 This antioxidant also is 
present in foods such as soybeans, walnuts, almonds, oils, 
fruits, and spinach.25 Despite low concentrations in LDL 
(0.5 to 0.8 mol/LDL particle), compared with LDL
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Selected Abbreviations and Acronyms
a-TOH = a-tocopherol
BHT
FCH
HDL-C
HPLC
LDL-C
PUFA
butylated hydroxytoluene 
familial combined hyperlipidemia (4) 
HDL cholesterol
high-performance liquid chromatography 
LDL cholesterol
polyunsaturated fatty acids; sum of C18:2 
and C20:4
Q10 = ubiquinone-10
QHr  10 
VLDL-C
ubiquinol-10 
VLDL cholesterol
VLDL-TG = VLDL triglycerides
a-TOH content (8 to 15 mol/LDL particle), QH2-10 has 
shown itself to be the first-line defense against oxidative 
stress in LDL.26 In volunteers, a long-term supplemen­
tation with Q10 resulted in a twofold increase in the 
plasma concentration of QH2-10.27 This was accompa­
nied by increased resistance of LDL against oxidation, 
initiated by aqueous peroxyl radicals, in vitro.27 Besides 
the contribution of antioxidants, LDL oxidizability in vi­
tro was found to be influenced by the fatty acid compo­
sition28 and the chemical composition of LDL.11
Although a specific marker to definitively ascertain the 
diagnosis of FCH is still lacking, a recent study shows 
that a predominance of small, dense LDL particles is 
characteristic for affected FCH relatives,4 especially 
when accompanied by hyperlipidemia. Regarding the ob­
servations on the relative constancy of the LDL subfrac­
tion profile in relation to that of plasma lipid concentra­
tions, especially that of plasma triglycerides (S.J.H. 
Bredie, P.N.M. Demacker, A.F.H. Stalenhoef, unpub­
lished observations, 1995), we assume that the presence 
of dense LDL is a helpful metabolic marker for identi­
fying affected relatives of FCH kindreds characterized by 
variability in plasma concentrations of lipids and choles­
terol. Therefore, FCH families offer a unique opportunity 
to investigate the oxidation characteristics of both dense 
LDL from subjects with or without hyperlipidemia and 
buoyant LDL from normolipidemic subjects, all present 
in these families.
Methods
Chemicals
Q10, D,L-a-TOI-I, and BHT were from Sigma Chemical Co; Q10 
was reduced to QHi-10, essentially as described by Frei et al.29 All 
reagents and HPLC solvents were of high analytical grade.
Subject Selection
All participants were selected from 40 well-defined FCH fam­
ilies, consisting of both affected and nonaffected relatives.4 Di­
agnosis of FCH was based on the following criteria: (1) the pres­
ence in first-degree relatives of a multiple-type hyperlipidemia 
with elevated levels of total plasma cholesteiol and/or triglycer­
ides using the age- and sex-related 90th percentile upper levels 
of the prospective cardiovascular Münster (PROCAM) study30 
and (2) a family history of premature cardiovascular disease be­
fore age 60. Families were excluded when first-degree family 
members had tendon xanthomata. None of the probands was ho­
mozygous for the apo E2 allele, and for all probands, a secondary 
cause (eg, diabetes mellitus, hypothyroidism, and hepatic or renal 
impairment) of the presence of the hyperlipidemia could be ex­
cluded by standard laboratory tests.
On the basis of the density of the LDL subfraction profiles 
and plasma lipid concentrations, 35 subjects from 13 families
were selected to participate in this study. Twelve subjects were 
characterized by a buoyant LDL subfraction profile and 23 
subjects by a dense LDL subfraction profile. The method of 
LDL subfractionation is described elsewhere in this article. 
All subjects with a buoyant LDL subfraction profile had nor­
mal lipids. Of the subjects with a dense LDL subfraction pro­
file, 7 subjects were normolipidemic and 16 subjects were hy- 
perlipidemic. This resulted in three groups of subjects; basal 
characteristics are summarized in Table 1. None of the sub­
jects were on drug treatment or on a special diet, and none of 
the subjects used vitamin supplements.
Plasma M easurem ents
Fasting blood samples were collected into evacuated tubes 
containing K3-EDTA (1 mg/mL). The tubes were immediately 
placed on ice in the dark. Thirty nonlocal participants were visited 
at their homes. At 2 hours after blood sampling, plasma was 
separated from blood cells by centrifugation at 3600 rpm for 8 
minutes at 4°C. Prior to the measurement of a-TOH and QH2-10 
concentrations in plasma, saccharose as cryopreservative (final 
concentration 6 mg/mL) and BI-IT as antioxidant (final concen­
tration 250 ¿/,g/mL) were added.
VLDL and IDL ( d s  1.019 g/mL) were isolated by ultracentri­
fugation. After removal of VLDL and IDL, cholesterol and tri­
glyceride levels were measured in the infranatant and in total 
plasma. HDL was isolated from whole plasma by the polyeth­
ylene glycol 6000 method.31 Cholesterol and triglyceride levels 
were determined by enzymatic methods (No. 237574, Boeh- 
ringer-Mannheim; No. 6669, Sera Pak, Miles, respectively). LDL 
cholesterol was calculated by subtraction.
Analysis of LDL Subfraction Profile
Each individual LDL subfraction profile was defined by a con­
tinuous variable, K, as described in detail by de Graaf et al.32 
Bi'iefly, LDL subfractions were separated by single-spin density- 
gradient ultracentrifugation, according to an earlier described 
method.33 After ultracentrifugation the LDL subfractions were 
visible as distinct bands in the middle of the tube. Up to five LDL 
subtractions could be distinguished. The tubes were photo­
graphed. Accurate documentation of the LDL subtraction distri­
bution was obtained by scanning the slides on an LKB 2202 
ultrascan laser densitometer (Pharmacia LKB).32 The relative 
peak heights of the LDL subfractions on the scans were used to 
calculate parameter K as a continuous variable, which best de­
scribes each individual LDL subfraction profile. A negative value 
(K<0) reflects a more dense subfraction profile and a positive K 
value (Ks:0) a more buoyant profile.32
Oxidation of LDL
Plasma isolation was immediately followed by LDL isola­
tion by density-gradient ultracentrifugation (40 000 rpm for 
18 hours at 4°C) using an SW40 rotor (Beckman).34 After iso­
lation of total LDL, the protein content of LDL was measured 
by the method of Lowry et al,35 with chloroform extraction to 
remove turbidity, using bovine serum albumin as a standard. 
The oxidation experiments were performed as described by 
Esterbauer et a l36 as modified by Princen et a l.34 Briefly, the 
oxidation of LDL (60 ¡xg apolipoprotein/niL) was initiated by 
the addition of C u S 0 4 to a final concentration of 18 /imol/L 
at 37°C. The kinetics of the oxidation of LDL was determined 
by monitoring the change of the 234-nm diene absorption in 
a thermostatically monitored UV spectrophotometer (Lambda 
12, Perkin Elmer GmbH), equipped with a nine-position au­
tomatic sample changer. Each LDL preparation was oxidized 
twice in two separate oxidation runs on the same day. Every 
oxidation run was controlled by analyzing one reference LDL, 
prepared from a pooled plasma stored at -80°C . The interas­
say coefficients of variation for the oxidation parameters lag 
time and oxidation rate, and maximal amount of conjugated 
dienes formed per milligram of protein of the reference LDL 
amounted to 1.2%, 5%, and 4.7%, respectively (n= I0 ). To
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T a b le  1. Characteristics of Subjects, Plasma Concentrations of Lipids and 
Lipoproteins, and the LDL Subtraction Profile (ie, K value)
Group 1 Group 2 Group 3
(n=12) (n=7) (n=16)
Age, y 41.4±12.7 39.4+12.9 46.2+11.8
Body mass index, kg/m2 23.5+2.2 24,8±2.7 25.8+2.8
Smokers, >10 cigarettes/d, % 16.7 14.3 18.8
Personal history of coronary heart disease, %* 0 14.3 31.2
Total cholesterol, mmol/L 5.16±0.96 5.59+0.64 6.67 ±1.341
Total triglycerides, mmol/L 1.30 ±0.53 1.60+0.26 3.66±1.15ti
VLDL-C, mmol/L 0.36±0.17 0.64+0.18 1.51 ±0.52t4'
VLDL-TG, mmol/L 0.76+0.41 1.01 ±0.22 2.86±1.05tt
LDL-C, mmol/L 3.28±0.82 3.87+0.61 4.25:1:1.30
HDL-C, mmol/L 1.34+0.28 1.04+0.22 0.87+0.14+
K value 0.06:1:0.07 -0.30+0.201" -0.64+0.16 t t
Group 1 indicates buoyant LDL subtraction profile, normolipidemic subjects; Group 2, dense LDL sub­
traction profile, normolipidemic subjects; and Group 3, dense LDL subtraction profile, FCH subjects. 
*P<.0001 (x s test); tP^-OOS vs group 1; and tPs.OOS vs group 2.
guarantee a high reproducibility of the oxidation assay, it ap­
peared to be necessary to clean the quartz cuvettes thoroughly 
after every three oxidation runs. For this purpose, cuvettes 
were immersed in 2% (vol/vol) Hellmanex (No. 329 .001, 
Hellma) for 30 minutes under continuous stirring on a hot 
plate at 80°C. Subsequently, cuvettes were thoroughly washed 
with deionized water for 15 minutes, followed by drying in a 
stream of filtered air.
Determination of a -T O H , Q H 2-10, and  Q10 in 
Plasma and LD L
To exclude any oxidation of QH2-10, antioxidants were deter­
mined in material as fresh as possible. Consequently, plasma sep­
aration was immediately followed by LDL isolation by density- 
gradient ultracentrifugation (40 000 rpm for 18 hours at 4°C). 
LDL was isolated by cautious aspiration. Before extraction, BI-IT 
was added to the LDL preparations to a final concentration of 
250 /ig/mL. The concentrations of Q-10 (oxidized form of co­
enzyme Q10) in plasma and LDL were determined by HPLC 
(Spectra Physics model 8800) with UV detection at 275 nm, se­
quentially followed by electrochemical detection (Decade, An- 
tec) for the determination of a-TOH and QH-.-10.17 In each run, 
samples obtained of group 2 and/or group 3 subjects were blindly 
analyzed together with samples obtained of group 1 subjects. 
Deoxygenated and transition-metal-free aqueous solvents were 
used. All treatments were performed on ice, in the dark, and under 
nitrogen.
Immediately after isolation, plasma or LDL (200 ¡xL) was 
mixed with 2.0 mL ice-cold methanol. Subsequently, 4.0 mL ice- 
cold n-hexane was added and the mixture was vortex-mixed for 
2 minutes. To exclude artifact due to instability, samples were 
extracted in series of maximal 10. Alter ceiUriftmation lor 2
W c-
minutes at 3600 rpm al 4°C, the hexane upper layer was collected 
and the extraction procedure was repeated. Both hexane layers 
were pooled and dried under a flow of nitrogen within 45 minutes 
at room temperature. The residue was stored al — 20°C until in­
jection within 4 hours. Just before injection onto the HPLC col­
umn, the residue was dissolved in the mobile phase, consisting 
of 22.5% (vol/vol) methanol and 77.5% (vol/vol) ethanol/isopro- 
panol (95:5) with 20 mmol/L lithiumperehlorate as electrolyte. 
Twenty microliters of sample was injected onto an Inertsil 
ODS-2 column (200X3.0 mm; 5-//m particle size) equipped with 
a reverse-phase guard column (10x2  mm) (both from Chrom- 
pack). a-TOH and QI-L-IO were eluted isocratically with the mo­
bile phase at a How rate of 0.35 mL/min. The eluate was moni­
tored with an electrochemical detector, A VT-03 How cell with 
GC working electrode (Antee) was used. The applied potential 
was 600 mV (versus Ag/AgCl in saturated LiCl). The interassay 
coefficients of variation for the determination of plasma and LDL 
concentrations of cv-TOH were 1.3% and 4.5% (n=6), respee-
tively; of Q H j-10, 5.9% and 4.4% (n=8), respectively; of Q10, 
3.1% and 5.6% (n=8), respectively.
Stability of Q H 2-10
Because of the suggested instability of QHj-10 in plasma and 
especially in LDL,2<,-1K we performed stability experiments to val­
idate our results. In whole blood, QI-L-IO was found to be stable 
for at least 4 hours in the dark at 4°C (99.6±3.1% to initial con­
centrations; n=6). QH2- 10 concentrations in plasma were stable 
during storage in the presence of 250 fig BHT/mL for up to I 
week at —80°C (98.0±3.0% to initial concentrations; n=3). To 
use similar LDL preparations for both the oxidation and antiox­
idant experiments, we isolated LDL by density-gradient ultracen­
trifugation in the absence of BUT. Q H j-10 concentrations in LDL 
were 104.1 ±4.6% (n=8) compared with those concentrations 
measured in LDL isolated in the presence of BHT. Prior to all 
extractions we added 250 ¿/g BHT/mL. QHr  10 concentrations 
in LDL, however, were s 
without BHT (99 .0±2 .1 % |n=3] versus BHT method). Until hex­
ane extraction of the LDL preparations, LDL was stored in 2 mL 
of methanol at — 20°C after mixing. Under these conditions, QH2- 
10 was found to be stable for at least 24 hours (100.4±3.8% of 
initial concentrations; n -6 ) .  Consequently, Q10 concentrations 
during the described storage conditions were stable. After the 
lipid extraction, the combined hexane layers were evaporated un­
der N-i(g) and residues were stored at -20°C  until analysis within 
4 hours. During this time, Q H r 10 concentrations were stable 
(98.0±2.0% of initial concentrations; n=6). However, storage of
the lipid residues for 24 hours at -20°C  resulted in a 43.5±8.7%
loss of the QHr 10 content. Consequently, the Q 10 content was
ar to at extraction
increar1'
D eterm ination of Fatty Acids in LDL
The concentrations of polyunsaturated ( C l8:2; C20:4) and of
monounsaturated (C l8:1) fatty acids in LDL were 
essentially as described in detail by tie Graaf et al."
Prior to statistical testing, plasma triglycerides and VLDL-TG
were transformed logarithmically because of skewing of the dis­
tributions. Differences in smoking and personal history of coro­
nary artery disease were calculated by a x z test. A one-way
ANOVA was used to analyze the differences in the studied pa­
rameters between the three groups, followed by additional Tu- 
key’s multiple comparison tests. All values are presented as 
mean±SD. Associations between variables were calculated with 
Pearson’s correlation coefficients. All statistical analyses, includ­
ing logistic regression analysis, were performed using SPSS/PC 
software (SPSS Inc).
130 Arteriosclerosis, Thrombosis, and Vascular Biology Vnl 17, No 1 January 1997
T a b le  2. Oxidation Characteristics of LDL Isolated From Normolipidemic and 
FCH Subjects
Group 1 Group 2 Group 3
(n=12) (n=7) (n-16)
Lag time, min
dienes (t=0), nmol/mg LDL protein 
dienesma)ti nmol/mg LDL protein
See Table 1 for definitions of groups. 
*P< .05 vs group 1; tP<-05 vs group 2.
70.4±11.4 66.6±14.1 60.4±8.1
Oxidation rate, nmol dienes*mg protein 1*min 1 22.5±2.3 23.6±2.0 21.4±2.5
175±12 178±11 167±12
710±70 738±59 646±61*t
Results
Plasm a Lipids, Lipoproteins, and K Values
Mean concentrations of plasma lipids and lipoproteins 
and the characterization of the LDL subfraction profiles of 
the respective groups are presented in Table 1. The per­
sonal history of coronary heart disease increased from 0% 
to 31% in groups 1 to 3, respectively. Compared with 
groups 1 and 2, group 3 subjects had, by selection, higher 
concentrations of total cholesterol, LDL-C, VLDL-C, total 
triglycerides, and VLDL-TG, lower concentrations of 
HDL-C, and more negative K-values (Table 1).
Oxidation Characteristics of LDL and LDL 
Antioxidant Contents
The mean lag time of LDL for oxidation was shorter in 
group 3 than in group 1 (Tukey, PC.05) (Table 2). In 
group 2, an intermediate mean lag time was measured 
which, probably due to the small group size, did not differ 
significantly from both other groups. When we considered 
groups 2 and 3 as one group, on the basis of characteriza­
tion of the LDL subfraction profile, we observed that the 
mean lag time of LDL to oxidation was shorter than that 
in group 1 (Table 3). Exclusion of the smokers in the re­
spective groups did not affect the presented results. The 
lag time of total LDL to oxidation correlated with the den­
sity of the LDL subfraction profile of the subjects, ex­
pressed as the continuous variable K (r=.35, PC.05). The 
maximal amount of dienes formed per milligram of LDL 
protein during oxidation of LDL isolated from FCH sub­
jects was lower than the amount of dienes formed in LDL 
from group 1. Oxidation rates of LDL and basal amounts 
of dienes in LDL were similar in the three groups.
We examined whether the oxidation characteristics of 
LDL could be attributed to differences in the basal a-TOH 
and QftU-lO concentrations. Plasma concentrations of 
QI-I2-10 were related to plasma concentrations of total cho­
lesterol (r=.41, PC.01) and a-TOH (r=.41, PC.01). The 
absolute and relative concentrations of a-TOH, QI-L-IO,
T a b le  3. Characteristics of Buoyant and Dense LDL 
Isolated From Normolipidemic and FCH Subjects
Buoyant LDL* 
(n=12)
Dense LDLf
(n=23)
K value 0.06±0.07 -0.54±0.24t
Lag time, min 70.4±11.4 62.3±10.4§
nmol QH2-10/g apolipoprotein 700±138 578±223§
nmol Q10/g apolipoprotein 191±99 304±144§
/j.mol Q10/mo! cholesterol 32.9±14.0 52.3±24.0§
QH2-10/Q10 3.2±1.0 1.9±1.0§
QHa-10/a-TOH 0.05±0.01 0.04±0.01t
and Q10 in plasma and LDL are given in Table 4, while 
the most important results are presented in the Figure. No 
differences were found between the three groups in the 
LDL a-TOH content, quantified relatively to cholesterol, 
apolipoprotein, or PUFA (Table 4). While the LDL QH2- 
10 content, relatively to apolipoprotein and 
PUFA, tended to be lower in group 2 than group 1 (Tukey, 
P —.07), the Q10 content was significantly increased (Ta­
ble 4). The fatty acid composition of LDL was similar in 
all three groups (Table 4). Remarkably, for all subjects 
with a dense LDL subfraction profile, both the ratio of 
LDL QHa-10 to a-TOH and the redox status of coenzyme 
Q10 in LDL (QH2-10/Q10 ratio) were lower than the ratios 
in LDL from subjects having a buoyant LDL subfraction 
profile (Figure). In line with this, the redox status of co­
enzyme Q10 correlated with the density of the LDL sub­
fraction profile (;*=.37, P<.05). In nonsmoking subjects 
the ratio of LDL QH2-10 to a-TOH was 0.05±0.01, 
0.03±0.01 (PC.05 versus group 1), and 0.04±0.01 for 
groups 1, 2, and 3, respectively. Furthermore, exclusion of 
the smokers in the three groups resulted in a redox status 
of coenzyme Q10 in LDL of 3.4±1.0, 1.5± 1.5 (PC.05 
versus group I), and 2.1 ±0.8 (Pc.005 versus group 1), 
respectively. Even when groups 2 and 3 are considered as 
one group, characterized by a dense LDL subfraction pro­
file (n=23), both ratios were significantly lower than those 
in group 1 (Table 4). Regarding our stability experiments 
(see “Methods” ), it is unlikely that the observed differ­
ences in the ratios were due to oxidation ex vivo. A second 
indication that the shift in the redox status of coenzyme 
Q10 was not an artifact appeared in the similarity of the 
redox ratios in total plasma versus the indicated LDL frac­
tion in the various groups.
In the combined groups, we observed that 53% of the 
variability in oxidation rate could be predicted by the basal 
amount of dienes in LDL together with the basal LDL 
QH2-10 to LDL PUFA content ratio (Pc.OOOl).
Discussion
Total LDL in FCH subjects (group 3) was less well pro­
tected against copper-mediated oxidation than total LDL 
from normolipidemic relatives with a buoyant LDL sub­
fraction profile (group 1). Even when the subjects of 
groups 2 and 3, all characterized by a dense LDL subfrac­
tion profile, were combined, their LDL was more prone to 
oxidation than the LDL of group 1 (P<.05). To our knowl­
edge, this is the first time a reduced oxidation resistance 
of total LDL, instead of isolated LDL subfractions, is pre­
sented for subjects characterized by a dense LDL subfrac­
tion profile. Possibly, the conformation of dense LDL par­
ticles facilitates the of to
*LDL isolated from group 1 subjects; tLDL isolated from group 2 and 
3 subjects. 
t.0005<P<.005; §.01<P<.05.
apolipoprotein B100, or the premature exhaustion of an­
tioxidants, thereby explaining the increased susceptibility 
to oxidation.-19
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Quantitatively, a-TOH is an important antioxidant in 
LDL.20 However, in line with observations of other groups 
with subjects on a normal diet, the susceptibility of LDL 
to oxidative modification was not related to the a-TOH 
content of LDL.-14'40-43 From in vitro oxidation studies, 
QH2-IO is shown to be an antioxidant of the first line.26 
LDL that was isolated from normolipidemic subjects with 
dense LDL tended to have a lower QH2-10 content, rela­
tive to the apolipoprotein B100 01* PUFA contents, than 
LDL from subjects with a buoyant profile. In addition, the 
redox status of coenzyme QIO (ratio of reduced form to 
oxidized form of coenzyme QIO) was substantially re­
duced in dense LDL particles, independent of whether 
LDL was isolated from normolipidemic or hyperlipidemie 
subjects (Figure). The oxidation of QI-L-10 within LDL 
particles was reported to be accompanied by the formation 
of lipid hydroperoxides within LDL.-1’ Our data on the 
redox status of coenzyme QI O and the consequences con­
cerning the initial degree of lipid peroxidation concur with 
data of Alieva et al.44 For normolipidemic subjects these 
authors showed that hydroperoxide concentrations were 
increased in dense LDL compared with buoyant LDL par­
ticles. An increased lipid hydroperoxide content in dense 
LDL may also explain the observed increased susceptibil­
ity of dense LDL to copper-mediated oxidation in vitro.4S 
In healthy subjects, elevated concentrations of plasma lipid 
hydroperoxides were measured, in vivo, when the redox 
status of coenzyme QIO was reduced.46 Thus, the redox 
status of coenzyme QIO in dense LDL appears to be a 
sensitive marker for oxidative changes that take place in 
LDL in vivo. By careful analysis, we have shown that the 
reduced redox status of coenzyme QIO in groups 2 and 3, 
versus that in group 1, cannot be explained by a higher 
artificial oxidation of QH2-10 during the several analysis 
steps. In this respect it is interesting to note the 3- to 30- 
fold-lower QH2-10 concentration in LDL of normolipid­
emic subjects™ compared with concentrations measured 
in other studies2i’-27 and in the present study. We ascribe 
this to the lengthy isolation procedure of 3 days, including 
the dialysis step. To prevent loss or oxidation of LDL QH2-
O
H M<0
k .
X0h1o
o’
0.06
0.05
0.04
Xo
cs
Q-J
0.03
0.02
0.01
6
5
o
a
o
o
o
' 3
- 2
1
0
Xo
_1Q
ci
Group 1 Group  2 G r o u p 3
Relative QH2-10 concentrations in LDL. LDL QHa-10 content was 
quantified relative to the o-TOH content (lefty axis, hatched bars), 
and the Q-10 content (redox status) (right y axis, filled bars). 
Group 1 indicates normolipidemic subjects with a buoyant LDL 
subtraction profile (n=12); Group 2, normolipidemic subjects with 
a dense profile (n=7); and Group 3, FCH subjects with a dense 
profile (n=16). * P < .05 vs group 1.
10, LDL was not dialyzed in our study. This may explain 
why we did not find any relation between lag time and 
QH2-10 content. In agreement with Kontush et al,47 we 
found that the basal LDL QI-L-10 to PUFA content ratio
« M
was negatively correlated with the rate of oxidative mod­
ification of LDL. QH2-I0 may indirectly protect the 
PUFAs against lipid peroxidation by efficient reduction of 
a-TOH radicals (reviewed in Reference 23). In line with 
results of Stocker and coworkers,26-27 our results stress the 
promising role of QH2-I0.
Whether a decrease in the redox status of coenzyme QIO 
in LDL, due to oxidation of QH2-10, results in minimally 
oxidized LDL needs to be studied. Compared with native 
LDL, mildly oxidized LDL exerts important biological ef­
fects, at least in vitro. It is believed that these are involved 
in the early stages of atherosclerosis.4H Minimally oxidized 
LDL was shown to stimulate the endothelial cell-mediated
attractant protein411 and mono-
• hand, it may
be possible that the radicals that result in oxidation of co­
enzyme QIO can also induce tryptophan residue destruc-
release of monocyte c 
cyte colony-stimulating factor.-™ On the
T a b le  4. Concentrations of ¿»--Tocopherol and Ubiquinol-10 in Plasma 
and Lipoproteins
Group 1 Group 2 Group 3
(n 12) (n 7) (n 16)
Plasma
tv-TQH, nmol/L 27.6' 10.3 27.5 ' 5.5 42.5 ' 9.0*
mmol (v-TOH/mol cholesterol 5.3 1.1.7 5.0' 1.1 6.511.4
QH;.-10, nmol/L 1035' 600 10201569 1159 * 479
/ymol QH:i-10/mol cholesterol 193 1 81 180'95 177 • 69
Q-10, nmol/L 350 ' 101 461'161 5931228*
//mol Q-10/mol cholesterol 
LDL
691 32 85 ' 35 91 ±34*
mmol «-TOH/mol cholesterol 1.9± 0.4 2.1 ±0.6 2.3 ±0.5
//mol a-TOH/g apolipoprotein 14.3± 3.1 14.5 ±2.6 15.213.3
mmol «-TOH/mol PUFA 7.0 ■1.6 6.8 ±2.1 7.51:1.5
//mol QH2-10/mol cholesterol 95.3 ± 18.0 69.6 • 38.0 92.2 ‘ 32.0
nmol QHt.-10/g apolipoprotein 700 ± 138 480±252 621±204
//mol QH2-10/mol PUFA 342 ± 88 227::'; 88 3081100
//mol Q-10/mol cholesterol 32.9 • 14 62.7 ' 25* 47.7 ■ 22
nmol Q-10/g apolipoprotein 191 :!99 351:1136* 2841:147
PUFA/C18:1 2.9 ± 0.5 3.21:0.4 3.01:0.4
C18:2/C18:1 2.6 ' 0.5 2.81:0.4 2.6 • 0.3
See Table 1 for definition of groups. 
*P<.05 vs group 1.
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tion.51 This process occurs in two phases; the earliest phase 
is independent of a'-TOH and plays an initial role in LDL
lipid peroxidation.51
In conclusion, dense LDL particles from subjects with 
FCH are less resistant to oxidation in vitro than buoyant 
LDL from normolipidemic relatives. Compared with sub­
jects with an overall buoyant LDL subfraction profile, the 
redox status of coenzyme QIO was reduced in subjects 
with an overall dense LDL subfraction profile, indepen­
dent of the plasma concentration of cholesterol or triglyc­
erides* This suggests that QH2-10 is an important indicator 
of oxidative modification in vivo. Future investigations to 
assess oxidative stress in subjects at risk for coronary heart 
disease should include the redox status of coenzyme QIO.
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